All In Biotech

Drug Trial Radar · NCT04722146

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

140

Actual

Start

Mar 12, 2021

Primary completion

Oct 3, 2025

Study completion Oct 13, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.

Conditions

  • Multiple Myeloma

Interventions

  • TeclistamabDrug

    Participants will receive teclistamab.

  • DaratumumabDrug

    Participants will receive daratumumab.

  • PomalidomideDrug

    Participants will receive pomalidomide.

  • LenalidomideDrug

    Participants will receive lenalidomide.

  • BortezomibDrug

    Participants will receive bortezomib.

  • NirogacestatDrug

    Participants will receive nirogacestat.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Incidence of Adverse Events (AEs)Time frame: Up to 2 year and 5 months
  2. Number of Participants with AEs by SeverityTime frame: Up to 2 year and 5 months
  3. Number of Participants with Abnormalities in Laboratory ValuesTime frame: Up to 2 year and 5 months
  4. Number of Participants with Dose-Limiting Toxicity (DLT)Time frame: Up to Cycle 2 Day 21 (each cycle is of 28 days for Treatment Regimen A and 21 days for Treatment Regimen B)

Locations

27 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California San Francisco

    San Francisco, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Winship Cancer Institute Emory University

    Atlanta, Georgia

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Washington University School Of Medicine

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Tennessee Oncology

    Nashville, Tennessee

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin

  • St Vincents Hospital Melbourne

    Fitzroy, Australia

  • Alfred Health

    Melbourne, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, Australia

  • UZA

    Edegem, Belgium

  • UZ Gent

    Ghent, Belgium

  • Centre Leon Berard

    Lyon, France

  • CHU Nantes

    Nantes, France

  • CHU de Bordeaux - Hospital Haut-Leveque

    Pessac, France

  • Chu Rennes Hopital Pontchaillou

    Rennes, France

  • Institut Universitaire du cancer de Toulouse-Oncopole

    Toulouse, France

  • University College Hospital

    London, United Kingdom

  • The Christie Nhs Foundation Trust

    Manchester, United Kingdom

  • The Royal Marsden NHS Trust Sutton

    Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.